Heron Therapeutics Inc vs Stanley Black & Decker, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.39 (market cap $68.01M), while Stanley Black & Decker, Inc. trades at $87.68 (market cap $13.47B). The key difference: Stanley Black & Decker, Inc. is far larger — about 198.1× Heron Therapeutics Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.77% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| HRTX | SWK | |
|---|---|---|
Market Cap | $68.01M | $13.47B |
Volume | 1,891,941 | 2,859,744 |
Sector | Health | Industrials |
52-Week High | $1.49 | $104.00 |
52-Week Low | $0.27 | $62.12 |
Typical Hold Time | 35 Days | 62 Days |
Enterprise Value | $174.75M | $17.63B |
Dividend Yield | — | 3.77% |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Stanley Black & Decker (SWK) trades at $88.31, down 1.87% on the day, with a bearish technical signal from moving averages and oscillators. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results expected November 4, 2026. Fundamentals show modest revenue of $15.13B in 2025 and a net income margin of 4.07%, while valuation ratios like a P/E of 21.8 and P/S of 0.89 suggest reasonable pricing. Recent news highlights product launches like the dustbuster® mini™ and management's focus on margin gains.
The outlook is mixed: analyst consensus is a 'Hold' with a $93 price target, implying ~5% upside, but technical weakness and competitive pressures pose risks. Investment appeal lies in its dividend king status and cost-saving initiatives, though investors face headwinds from higher expenses and market volatility. Earnings growth remains the key catalyst for further upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →